Meeting
2014 ASCO Annual Meeting
Clinical impact of gastric acid suppressing medication use on the efficacy of elrotinib and gefitinib in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Authors
Yoshitaka Zenke
National Cancer Center Hospital East, Kashiwa, Japan
Yoshitaka Zenke , Kiyotaka Yoh , Shingo Matsumoto , Shigeki Umemura , Seiji Niho , Koichi Goto , Hironobu Ohmatsu , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8108)
DOI
10.1200/jco.2014.32.15_suppl.8108
Abstract #
8108
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
First Author: Julien Mazieres
Poster
2012 ASCO Annual Meeting
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
First Author: Stephanie Heon
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura
Poster
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
First Author: Li Zhang